Matinas BioPharma Holdings Inc
AMEX:MTNB
Intrinsic Value
The intrinsic value of one MTNB stock under the Base Case scenario is 14.06 USD. Compared to the current market price of 1.75 USD, Matinas BioPharma Holdings Inc is Undervalued by 88%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Matinas BioPharma Holdings Inc
Loading...
Fundamental Analysis

Revenue & Expenses Breakdown
Matinas BioPharma Holdings Inc
Balance Sheet Decomposition
Matinas BioPharma Holdings Inc
Current Assets | 8m |
Cash & Short-Term Investments | 7.3m |
Other Current Assets | 741k |
Non-Current Assets | 4.6m |
PP&E | 2.2m |
Intangibles | 2.3m |
Other Non-Current Assets | 200k |
Free Cash Flow Analysis
Matinas BioPharma Holdings Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Matinas BioPharma Holdings Inc
Revenue
|
0
USD
|
Operating Expenses
|
-20.2m
USD
|
Operating Income
|
-20.2m
USD
|
Other Expenses
|
-4.1m
USD
|
Net Income
|
-24.3m
USD
|
MTNB Profitability Score
Profitability Due Diligence
Matinas BioPharma Holdings Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Matinas BioPharma Holdings Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
MTNB Solvency Score
Solvency Due Diligence
Matinas BioPharma Holdings Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
Matinas BioPharma Holdings Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MTNB Price Targets Summary
Matinas BioPharma Holdings Inc
Dividends
Current shareholder yield for MTNB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one MTNB stock under the Base Case scenario is 14.06 USD.
Compared to the current market price of 1.75 USD, Matinas BioPharma Holdings Inc is Undervalued by 88%.